This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: National University of Singapore. Active years: 2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2019
Title: Cheng Shang See: Innovator in Anti-Cancer Compounds
Introduction
Cheng Shang See is a notable inventor based in Singapore, recognized for his contributions to the field of anti-cancer research. His innovative work focuses on developing selective anti-cancer compounds that hold promise for treating hyperproliferative diseases. With a single patent to his name, Cheng is making strides in the medical and pharmaceutical industries.
Latest Patents
Cheng's patent, titled "Selective anti-cancer compounds," describes a compound of formula I. This compound has a specific structure, wherein R to R, Y, L, Z, and X to X have meanings provided in the detailed description. The compounds are designed to have utility in the treatment of hyperproliferative diseases, showcasing Cheng's commitment to advancing cancer treatment options. He holds 1 patent in this area.
Career Highlights
Cheng Shang See is affiliated with the National University of Singapore, where he contributes to research and development in the field of cancer therapeutics. His work is pivotal in exploring new avenues for effective treatments, and he is dedicated to improving patient outcomes through innovative solutions.
Collaborations
Cheng has collaborated with esteemed colleagues, including Sang Hyun Lee and Brian William Dymock. These partnerships enhance the research efforts and broaden the impact of their findings in the scientific community.
Conclusion
Cheng Shang See is a significant figure in the realm of anti-cancer research, with a focus on developing innovative compounds for treatment. His work at the National University of Singapore and his patent on selective anti-cancer compounds highlight his dedication to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
